Atrial flutter is a macroreentrant supraventricular tachycardia most commonly involving a circuit around the tricuspid annulus through the cavotricuspid isthmus (CTI), producing the classic sawtooth flutter waves on ECG at atrial rates of 250–350 bpm with a typical ventricular rate of ~150 bpm (2:1 AV conduction). [1-3] It is the second most common pathologic SVT, frequently coexists with atrial fibrillation, and carries a similar thromboembolic risk. [2][4]
The following figure illustrates the flutter circuit anatomy and corresponding ECG morphology for typical and atypical flutter:
1. History
- Onset and duration: Abrupt or gradual? First episode or recurrent? Duration <48 hours vs ≥48 hours (critical for anticoagulation decisions before cardioversion) [6]
- Symptom characterization: Palpitations, dyspnea, chest pain, fatigue, lightheadedness, exercise intolerance, presyncope/syncope [7]
- Triggers: Alcohol, caffeine, stimulants, recent surgery (especially cardiac), acute illness, thyrotoxicosis, pulmonary embolism
- Associated symptoms: Orthopnea, PND, lower extremity edema (HF decompensation), focal neurologic deficits (stroke/TIA)
- Important negatives: No syncope, no chest pain at rest, no acute neurologic symptoms, no recent cardiac surgery
2. Alarm Features
- Hemodynamic instability: Hypotension, altered mental status, acute pulmonary edema, signs of cardiogenic shock → immediate synchronized cardioversion [2][8]
- 1:1 AV conduction: Ventricular rate 250–300 bpm — can occur with class IC antiarrhythmics (flecainide, propafenone) used without AV nodal blockers, or with accessory pathways → life-threatening [7][9]
- Pre-excitation (WPW): AV nodal blockers (diltiazem, verapamil, beta-blockers, digoxin, IV amiodarone) are contraindicated — risk of VF [10]
- Acute stroke symptoms: Suggests thromboembolic complication
- New-onset HF or tachycardia-mediated cardiomyopathy: Persistent uncontrolled flutter can cause reversible cardiomyopathy [1][7]
3. Medications
Acute Rate Control (hemodynamically stable)
- IV diltiazem (preferred calcium channel blocker): 0.25 mg/kg IV bolus, then infusion 5–15 mg/hr [1-2][4]
- IV metoprolol or esmolol (preferred IV beta-blocker for rapid onset) [1-2]
- IV amiodarone: Reserved for patients with HF/reduced EF where CCBs and beta-blockers are contraindicated [4][10]
- IV digoxin: Slow onset; adjunctive role only [4]
- IV magnesium: Reasonable adjunct to standard rate-control agents [4]
Acute Rhythm Control (chemical cardioversion)
- IV ibutilide: ~60% conversion rate; risk of torsades de pointes (monitor ≥4 hours post-dose); pretreat with magnesium [1-2]
- Oral dofetilide: Effective but requires inpatient initiation with QTc monitoring [1-2]
Contraindicated medications
- IV nondihydropyridine CCBs (diltiazem, verapamil) in moderate-severe LV systolic dysfunction or decompensated HF [4][10]
- Class IC agents (flecainide, propafenone) without concomitant AV nodal blocker — risk of 1:1 conduction [1][9]
- AV nodal blockers in pre-excited atrial flutter (WPW) [10]
Long-term medications
- Amiodarone, dofetilide, or sotalol for maintenance of sinus rhythm if ablation is not pursued [2]
- Beta-blockers, diltiazem, or verapamil for chronic rate control [2]
4. Diet
- Alcohol: Known trigger; counsel moderation or abstinence
- Caffeine: May exacerbate symptoms in some patients; individualized counseling
- Hydration: Dehydration can precipitate episodes
- If on warfarin: Consistent vitamin K intake; not applicable with DOACs
5. Review of Systems
- Cardiovascular: Palpitations, chest pain, dyspnea on exertion, orthopnea, edema
- Neurologic: Focal weakness, speech changes, vision changes (stroke screening)
- Pulmonary: Cough, wheezing, pleuritic pain (PE, COPD exacerbation as triggers)
- Endocrine: Heat intolerance, weight loss, tremor (thyrotoxicosis)
- GI: Bleeding symptoms (relevant if anticoagulation planned)
6. Collateral History and Family History
- Prior arrhythmia history, prior ablations, cardiac surgery
- Current medications (especially antiarrhythmics, stimulants, supplements)
- Family history: Sudden cardiac death, cardiomyopathy, WPW, early-onset AF/flutter
- Substance use: Alcohol, cocaine, amphetamines
- Functional baseline and exercise tolerance
7. Risk Factors
- Advancing age, male sex
- Hypertension, coronary artery disease, valvular heart disease
- Heart failure (HFrEF and HFpEF)
- COPD, obstructive sleep apnea
- Obesity, diabetes mellitus
- Prior cardiac surgery (especially atrial surgery — Fontan, Senning, mitral valve) [2][7]
- Prior AF ablation (atypical flutter circuits from scarring) [2]
- Thyrotoxicosis, pulmonary embolism, sepsis
- Antiarrhythmic drug use (flecainide, propafenone, amiodarone for AF can provoke flutter) [2][11]
8. Differential Diagnosis
Key pearl: A regular narrow-complex tachycardia at ~150 bpm should always raise suspicion for atrial flutter with 2:1 block, as flutter waves may be hidden in T waves. [3]
9. Past Medical History
- Prior AF or flutter episodes, prior cardioversions, prior ablations
- Structural heart disease, valvular disease, cardiomyopathy
- Prior cardiac surgery (CABG, valve repair/replacement)
- Congenital heart disease (especially post-surgical)
- Thyroid disease, COPD, OSA
- Stroke/TIA history (impacts anticoagulation urgency)
- Bleeding history (impacts anticoagulation risk)
10. Physical Exam
- Vitals: Heart rate (~150 bpm classic), blood pressure (hypotension = unstable), SpO₂, respiratory rate
- Cardiovascular: Regular or regularly irregular rhythm, signs of HF (JVD, S3, peripheral edema, pulmonary crackles), murmurs
- Pulmonary: Crackles (pulmonary edema), wheezing (COPD)
- Neurologic: Focal deficits (stroke screening)
- Thyroid: Goiter, tremor, exophthalmos
- Extremities: Peripheral edema, signs of DVT (PE as trigger)
- Skin: Cool/clammy (poor perfusion), diaphoresis
11. Lab Studies
- BMP/CMP: Electrolytes (K⁺, Mg²⁺ — correct before cardioversion), renal function (dosing adjustments for dofetilide, DOACs)
- TSH: Rule out thyrotoxicosis
- CBC: Anemia (high-output trigger), baseline before anticoagulation
- Troponin: If chest pain or concern for demand ischemia
- BNP/NT-proBNP: If HF suspected
- Coagulation studies: INR if on warfarin; baseline before anticoagulation
- D-dimer: If PE suspected as trigger
12. Imaging
- Chest X-ray: Cardiomegaly, pulmonary edema, pulmonary pathology
- Transthoracic echocardiogram (TTE): Assess LV function (critical — determines medication choice), valvular disease, LA size, RV function
- Transesophageal echocardiogram (TEE): Required before cardioversion if flutter ≥48 hours or unknown duration and patient not anticoagulated for ≥3 weeks [6][11]
- CT pulmonary angiography: If PE suspected as precipitant
- Imaging is not needed to diagnose atrial flutter — ECG is diagnostic
13. Special Tests
CHA₂DS₂-VASc Score — used identically to AF for thromboembolic risk stratification and anticoagulation decisions: [4]
- Adenosine: Can be used diagnostically to transiently block AV conduction and unmask flutter waves when diagnosis is uncertain (will not terminate flutter, unlike AVNRT) [15]
- Carotid sinus massage: May slow ventricular rate and reveal flutter waves [16-17]
- Electrophysiology study: For definitive diagnosis and ablation planning
14. ECG
Classic findings
- Sawtooth flutter waves (F waves): Best seen in leads II, III, aVF (negative/inverted in typical counterclockwise flutter) and V1 (positive) [1-2][12]
- Atrial rate: 250–350 bpm (typically ~300 bpm) [1][12]
- Ventricular rate: Most commonly ~150 bpm with 2:1 AV block; variable block produces irregular rates [3][12]
- No isoelectric baseline between flutter waves in inferior leads [12]
- Reverse typical flutter: Positive F waves in inferior leads, negative in V1 [1-2]
Dangerous patterns
- 1:1 conduction (rate 250–300 bpm): Life-threatening — seen with class IC drugs or accessory pathways [7]
- Wide QRS flutter: Consider pre-excitation or aberrant conduction
- Very slow flutter rate (<200 bpm): Consider antiarrhythmic drug effect or severe atrial disease [1][11]
Diagnostic pearl: If flutter waves are not obvious at ~150 bpm, administer adenosine or perform vagal maneuvers to transiently increase AV block and reveal the sawtooth pattern. [3][15]
The following figure from the 2015 ACC/AHA/HRS SVT Guideline illustrates the acute management algorithm for atrial flutter:
15. Assessment
- Typical (CTI-dependent) flutter accounts for >90% of cases; atypical flutter occurs post-cardiac surgery or post-ablation [1-2][4]
- Atrial flutter is more difficult to rate-control than AF due to less concealed AV nodal conduction [2][9]
- Carries the same thromboembolic risk as AF — anticoagulate using the same CHA₂DS₂-VASc criteria [1][4]
- Up to 50% of patients with atrial flutter will develop AF, and up to 82% after CTI ablation over long-term follow-up [2][4]
- Persistent uncontrolled flutter can cause tachycardia-mediated cardiomyopathy, which is reversible with rate/rhythm control [1][7]
Severity stratification
- Hemodynamically unstable → immediate cardioversion
- Stable with RVR → rate control ± cardioversion
- Stable, rate-controlled → outpatient management with anticoagulation and electrophysiology referral
16. Treatment Plan
Hemodynamically unstable
- Synchronized cardioversion at 50–100 J (lower energy often effective for flutter vs AF) — do not delay for anticoagulation [1-2][8]
- Initiate anticoagulation as soon as possible and continue ≥4 weeks post-cardioversion [6][11]
Hemodynamically stable — Rate Control
- First-line: IV diltiazem or IV beta-blocker (metoprolol/esmolol) [2][4]
- HF with reduced EF: IV amiodarone (avoid CCBs); beta-blockers with caution if decompensated [4][10]
- Adjunct: IV magnesium [4]
- Note: Rate control is often more difficult in flutter than AF; cardioversion may be needed [9]
Hemodynamically stable — Rhythm Control
- Electrical cardioversion: Preferred; often successful at lower energies than AF [1-2]
- IV ibutilide: ~60% conversion; monitor for torsades ≥4 hours; pretreat with magnesium [1-2]
- Oral dofetilide: Inpatient initiation required [1-2]
- Rapid atrial pacing: Effective in >50% of cases when pacing wires are in place (post-cardiac surgery, pacemaker/ICD) [1-2]
Anticoagulation
- Flutter ≥48 hours or unknown duration: Anticoagulate ≥3 weeks before and ≥4 weeks after cardioversion, OR perform TEE to exclude thrombus before cardioversion [6][11]
- Flutter <48 hours with high CHA₂DS₂-VASc: Heparin or DOAC before cardioversion [6]
- Long-term anticoagulation based on CHA₂DS₂-VASc score, same as AF [4]
Definitive therapy
- CTI ablation: Single-procedure success rate >90%, preferred over long-term antiarrhythmics for symptomatic or refractory flutter [1-2]
- Post-ablation: Continue anticoagulation ≥4 weeks; monitor for AF development long-term [4]
17. Disposition
Admit if
- Hemodynamic instability or required cardioversion
- New-onset HF or decompensated HF
- Refractory to rate control
- Significant comorbidities (ACS, PE, sepsis as trigger)
- Need for ibutilide or dofetilide initiation (telemetry monitoring required)
- Uncertain duration requiring TEE before cardioversion
Discharge if
- Rate-controlled (<110 bpm at rest), hemodynamically stable, asymptomatic
- Known recurrent flutter with established management plan
- Anticoagulation initiated or already therapeutic
- Reliable follow-up with cardiology/electrophysiology arranged
Observation
- New-onset flutter, rate-controlled, awaiting echocardiogram or cardiology consultation
- Post-cardioversion monitoring (minimum 4 hours post-ibutilide)
Consult electrophysiology
- Recurrent or refractory flutter
- Consideration for CTI ablation
- Atypical flutter (post-surgical, post-ablation)
- Pre-excitation with flutter
18. Follow Up / Return Precautions
Follow-up timing
- Cardiology/EP follow-up within 1–2 weeks for new-onset flutter
- Sooner if cardioverted or anticoagulation initiated
- Long-term AF monitoring recommended after flutter treatment (up to 50% develop AF) [2][4][9]
Return precautions — instruct patients to return for
- Rapid palpitations, chest pain, or shortness of breath
- Lightheadedness, near-syncope, or syncope
- Signs of stroke: facial droop, arm weakness, speech difficulty
- Signs of bleeding if on anticoagulation: blood in stool/urine, severe bruising, prolonged bleeding
Patient counseling
- Importance of medication adherence (rate control agents and anticoagulation)
- Avoid triggers: excessive alcohol, stimulants, dehydration
- Expected recovery: Rate-controlled flutter is manageable; ablation is curative in >90% of typical cases [1-2]
- Anticoagulation is often lifelong given high risk of concurrent/future AF [4]
References
1. 2015 ACC/AHA/HRS Guideline for the Management of Adult Patients With Supraventricular Tachycardia: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. — Page RL, Joglar JA, Caldwell MA, et al. Journal of the American College of Cardiology. 2016.
2. 2015 ACC/AHA/HRS Guideline for the Management of Adult Patients With Supraventricular Tachycardia: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. — Page RL, Joglar JA, Caldwell MA, et al. Heart Rhythm. 2016.
3. Evaluation and Initial Treatment of Supraventricular Tachycardia. — Link MS. The New England Journal of Medicine. 2012.
4. 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. — Writing Committee Members, Joglar JA, Chung MK, et al. Journal of the American College of Cardiology. 2024.
5. Atrial Flutter and Atrial Tachycardia. — Elias Hanna Practical Cardiovascular Medicine 2e. 2022.
6. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. — Writing Group Members, January CT, Wann LS, et al. Heart Rhythm. 2019.
7. ACC/AHA/ESC Guidelines for the Management of Patients With Supraventricular Arrhythmias--Executive Summary. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Supraventricular Arrhythmias) Developed in Collaboration With NASPE-Heart Rhythm Society. — Blomström-Lundqvist C, Scheinman MM, Aliot EM, et al. Journal of the American College of Cardiology. 2003.
8. Part 3: Adult Basic and Advanced Life Support: 2020 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. — Panchal AR, Bartos JA, Cabañas JG, et al. Circulation. 2020.
9. Atrial Fibrillation Occurring During Acute Hospitalization: A Scientific Statement From the American Heart Association. — Chyou JY, Barkoudah E, Dukes JW, et al. Circulation. 2023.
10. Part 9: Adult Advanced Life Support: 2025 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. — Wigginton JG, Agarwal S, Bartos JA, et al. Circulation. 2025.
11. 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. — January CT, Wann LS, Alpert JS, et al. Circulation. 2014.
12. 2011 ACCF/AHA/HRS Focused Updates Incorporated Into the ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Partnership With the European Society of Cardiology and in Collaboration With the European Heart Rhythm Association and the Heart Rhythm Society. — Fuster V, Rydén LE, Cannom DS, et al. Journal of the American College of Cardiology. 2011.
13. 2015 ACC/AHA/HRS Guideline for the Management of Adult Patients With Supraventricular Tachycardia: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. — Page RL, Joglar JA, Caldwell MA, et al. Heart Rhythm. 2016.
14. Diagnosis and Management of Paroxysmal Supraventricular Tachycardia. — Peng G, Zei PC. The Journal of the American Medical Association. 2024.
15. Approach to Narrow and Wide QRS Complex Tachyarrhythmias. — Elias Hanna Practical Cardiovascular Medicine 2e. 2022.
16. Diagnosis of Arrhythmias in Clinical Practice. — Antoni Bayés De Luna, Miquel Fiol‐Sala, Antoni Bayés‐Genís, et al. Clinical Electrocardiography. 2021.
17. Active Supraventricular Arrhythmias. — Antoni Bayés De Luna, Miquel Fiol‐Sala, Antoni Bayés‐Genís, et al. Clinical Electrocardiography. 2021.
18. 2015 ACC/AHA/HRS Guideline for the Management of Adult Patients With Supraventricular Tachycardia: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. — Page RL, Joglar JA, Caldwell MA, et al. Journal of the American College of Cardiology. 2016.